Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247208 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL7749229 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL30896646 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL1246378 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL6602399 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL25124368 | 1.00 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM3GRIN1 | |
| SCHEMBL8072720 | 0.97 | — | — | |
| SCHEMBL5257989 | 0.97 | — | — | |
| SCHEMBL455134 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20767612 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190135-A1 | LASSO STRUCTURES AND THEIR SYNTHESIS | CHROMACON AG (CH) | 2020-06-18 | — | — | US | claimed |
| EP-3541828-A1 | LASSO STRUCTURES AND THEIR SYNTHESIS | ChromaCon AG (CH) | 2019-09-25 | — | — | EP | claimed |
| WO-2018091339-A1 | LASSO STRUCTURES AND THEIR SYNTHESIS | CHROMACON AG (CH) | 2018-05-24 | — | — | WO | claimed |
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | TECAN SP, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20160282371-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | QUANTALYTICAL LABS INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160282371-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | QUANTALYTICAL LABS INC. (US) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190293667-A1 | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits | CYP2C8, CES2, UGT1A8 | CHRM2 2186/4885CHRM4 1139/4885CHRM5 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.